Alterity Therapeutics Limited

NASDAQ:ATHE

Biotechnology

Healthcare
$3.12 +9.89%

+$0.53 today

Market cap
$52.77M
Beta
-0.03
P/E (TTM)
-9.9
EPS (TTM)
-$0.07
52W Low $2.66High $7.00

Volume 0.02M

Average 0.05M

ATHE Long-term Debt

Borrowings due after more than one year.

Alterity Therapeutics LimitedNASDAQ: ATHE

Long-term Debt · Q2 FY2026 · quarter ended Dec 2025

Long-term debt remains negative

Q2 FY2026 long-term debt was A$0, compared with A$0 a year earlier.

Context

  • Long-term debt amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Long-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
A$0— QoQ
Last fiscal yearJun 2025
A$0— YoY
Year agoDec 2024
A$0— since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

AUD · from the balance sheet

Latest · FY2025
0 AUD
Year-over-year change
—

Long-term Debt vs competitors

How ATHE compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
  • Long-term debt amounts to 0.0% of total assets for ATHE, versus a peer median of 0.0%.
ATHE Competitors
Long-term Debt for ATHE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
DYAIDyadic International, Inc.Mar 2026$5.03M USD+0.9%—64.5%
ATHEAlterity Therapeutics LimitedDec 2025A$0 AUD——0.0%
MAIAMAIA Biotechnology, Inc.Mar 2026$0 USD——0.0%
ANVSAnnovis Bio, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding ATHE) —+0.9%—0.0%

Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Cash & Equivalents28.12M34.81M15.77M12.64M33.16M
Short-term Investments00007.5M
Net Receivables4.13M4.67M8.65M4.04M3.94M
Inventory00000
Other Current Assets160.67K66.19K56.6K40.67K41.82K
Total Current Assets33.49M41.14M27.05M19.04M45.87M
Property, Plant & Equipment (Net)96.81K218.52K268.86K186.88K155.17K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets96.81K218.52K268.86K186.88K155.17K
Total Assets33.59M41.36M27.32M19.22M46.03M
Account Payables1.45M2.64M1.72M581.14K538.28K
Short-term Debt00000
Tax Payables026.92K27.93K15.99K16.28K
Deferred Revenue0(57.63K)(107.18K)00
Other Current Liabilities33.85K2.5M169.02K4.12M876.05K
Total Current Liabilities3.07M5.82M4.38M5.37M3.53M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities9.77K13.75K19.5K00
Total Non-current Liabilities47.67K73.61K122.71K51.91K88.55K
Total Liabilities3.12M5.89M4.5M5.43M3.62M
Common Stock197.45M213.79M213.97M223.15M262.95M
Retained Earnings(169.73M)(181.88M)(195.13M)(214.16M)(225.89M)
Accumulated OCI2.75M3.57M3.97M4.81M5.34M
Other Stockholders Equity00000
Minority Interest00000
Total Equity30.47M35.47M22.81M13.8M42.4M
Total Debt65.65K117.49K210.38K159.05K155.46K
Net Debt(28.05M)(34.69M)(15.56M)(12.48M)(33M)

Alterity Therapeutics Limited

NASDAQ:ATHE

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.